MX2024011520A - Conjugados de anticuerpos para el direccionamento contra tumores que expresan trop-2 - Google Patents
Conjugados de anticuerpos para el direccionamento contra tumores que expresan trop-2Info
- Publication number
- MX2024011520A MX2024011520A MX2024011520A MX2024011520A MX2024011520A MX 2024011520 A MX2024011520 A MX 2024011520A MX 2024011520 A MX2024011520 A MX 2024011520A MX 2024011520 A MX2024011520 A MX 2024011520A MX 2024011520 A MX2024011520 A MX 2024011520A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- targeting
- conjugates
- antibody conjugates
- trop
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title abstract 5
- 230000008685 targeting Effects 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 abstract 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 abstract 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 abstract 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 abstract 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 abstract 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 abstract 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 abstract 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 abstract 1
- 229950009429 exatecan Drugs 0.000 abstract 1
- 150000002772 monosaccharides Chemical class 0.000 abstract 1
- 229950006780 n-acetylglucosamine Drugs 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22163943 | 2022-03-23 | ||
| PCT/EP2023/057561 WO2023180485A1 (en) | 2022-03-23 | 2023-03-23 | Antibody-conjugates for targeting of tumours expressing trop-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024011520A true MX2024011520A (es) | 2025-01-09 |
Family
ID=81308125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011520A MX2024011520A (es) | 2022-03-23 | 2024-09-19 | Conjugados de anticuerpos para el direccionamento contra tumores que expresan trop-2 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250090679A1 (enExample) |
| EP (1) | EP4496594A1 (enExample) |
| JP (1) | JP2025510700A (enExample) |
| KR (1) | KR20250024743A (enExample) |
| CN (1) | CN119212731A (enExample) |
| AU (1) | AU2023241225A1 (enExample) |
| CA (1) | CA3253220A1 (enExample) |
| IL (1) | IL315207A (enExample) |
| MX (1) | MX2024011520A (enExample) |
| WO (1) | WO2023180485A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020094670A1 (en) | 2018-11-05 | 2020-05-14 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| IL315366A (en) | 2022-03-23 | 2024-11-01 | Synaffix Bv | Antibody pairs for targeting PTK7-expressing tumors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939255A (en) | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| ATE265532T1 (de) | 1995-10-19 | 2004-05-15 | Bristol Myers Squibb Co | Monoklonaler antikörper br110 und dessen anwendung |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| WO2008029281A2 (en) | 2006-02-10 | 2008-03-13 | Invitrogen Corporation | Labeling and detection of post translationally modified proteins |
| US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US7420041B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| WO2009102820A2 (en) | 2008-02-11 | 2009-08-20 | Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services | Modified sugar substrates and methods of use |
| CA2750038C (en) | 2009-02-05 | 2016-10-04 | Oncoxx S.R.L. | Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors |
| JPWO2011155579A1 (ja) | 2010-06-10 | 2013-08-15 | 北海道公立大学法人 札幌医科大学 | 抗Ｔｒｏｐ−２抗体 |
| US8871908B2 (en) | 2011-11-11 | 2014-10-28 | Rinat Neuroscience Corp. | Antibodies specific for Trop-2 and their uses |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| ES2659270T5 (en) | 2012-10-23 | 2026-02-11 | Synaffix Bv | Modified antibody, antibody-conjugate and process for the preparation thereof |
| US9107960B2 (en) | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| PT3088419T (pt) | 2013-12-25 | 2019-01-11 | Daiichi Sankyo Co Ltd | Conjugado de anticorpo anti-trop2-fármaco |
| KR20170030648A (ko) | 2014-08-04 | 2017-03-17 | 시나픽스 비.브이. | 베타-(1,4)-n-아세틸갈락토오스아미닐트랜스퍼라아제, 또는 이의 돌연변이체를 이용한 당 단백질의 변형 방법 |
| ES2740907T3 (es) | 2014-10-03 | 2020-02-07 | Synaffix Bv | Enlazador de sulfamida, conjugados de los mismos y métodos de preparación |
| HUE038511T2 (hu) | 2015-04-23 | 2018-10-29 | Synaffix Bv | (1,4)-N-acetil-galaktóz-aminil-transzferáz vagy (1,4)-N-acetil-galaktóz-aminil-transzferázból származó glikoziltranszferázt alkalmazó, glikoprotein módosítására szolgáló eljárás |
| WO2017214491A1 (en) | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| WO2020094670A1 (en) * | 2018-11-05 | 2020-05-14 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| CR20210541A (es) | 2019-03-29 | 2021-12-20 | Medimmune Ltd | Compuestos y conjugados de estos |
| HUE065484T2 (hu) | 2019-04-26 | 2024-05-28 | Immunogen Inc | Camptothecin-származékok |
| CN116209679A (zh) | 2020-06-05 | 2023-06-02 | 财团法人生物技术开发中心 | 含有抗间皮素抗体的抗体-药物共轭物及其用途 |
| NL2026947B1 (en) | 2020-11-20 | 2022-07-01 | Synaffix Bv | Tyrosine-based antibody conjugates |
| CN113816969B (zh) | 2021-04-30 | 2024-01-16 | 联宁（苏州）生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
| JP7451677B2 (ja) | 2021-07-19 | 2024-03-18 | 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 | 二成分毒素を担った抗体薬物複合体及びその応用 |
-
2023
- 2023-03-23 CN CN202380028866.0A patent/CN119212731A/zh active Pending
- 2023-03-23 AU AU2023241225A patent/AU2023241225A1/en active Pending
- 2023-03-23 JP JP2024556005A patent/JP2025510700A/ja active Pending
- 2023-03-23 EP EP23714682.4A patent/EP4496594A1/en active Pending
- 2023-03-23 IL IL315207A patent/IL315207A/en unknown
- 2023-03-23 KR KR1020247034725A patent/KR20250024743A/ko active Pending
- 2023-03-23 WO PCT/EP2023/057561 patent/WO2023180485A1/en not_active Ceased
- 2023-03-23 CA CA3253220A patent/CA3253220A1/en active Pending
-
2024
- 2024-09-19 MX MX2024011520A patent/MX2024011520A/es unknown
- 2024-09-20 US US18/892,270 patent/US20250090679A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023180485A1 (en) | 2023-09-28 |
| EP4496594A1 (en) | 2025-01-29 |
| CN119212731A (zh) | 2024-12-27 |
| AU2023241225A1 (en) | 2024-08-29 |
| CA3253220A1 (en) | 2023-09-28 |
| US20250090679A1 (en) | 2025-03-20 |
| IL315207A (en) | 2024-10-01 |
| JP2025510700A (ja) | 2025-04-15 |
| KR20250024743A (ko) | 2025-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024011518A (es) | Conjugados de anticuerpos para el tratamiento de tumores que expresan ptk7. | |
| AU2025203017A9 (en) | Improved antibody-oligonucleotide conjugate | |
| Maglinao et al. | A platform to screen for C-type lectin receptor-binding carbohydrates and their potential for cell-specific targeting and immune modulation | |
| Lin et al. | Carbohydrate-based polymers for immune modulation | |
| PH12021551159A1 (en) | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions | |
| CO2021013823A2 (es) | Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos | |
| MX2023009113A (es) | Conjugados y compuestos inmunoestimulantes. | |
| Maity et al. | Heteroglycan of an edible mushroom Entoloma lividoalbum: Structural characterization and study of its protective role for human lymphocytes | |
| WO1999055715A2 (en) | Polysaccharide-antigen conjugates | |
| Tom et al. | Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation | |
| Pérez-Bassart et al. | Composition, structural properties and immunomodulatory activity of several aqueous Pleurotus β-glucan-rich extracts | |
| US20210402002A1 (en) | Conjugate | |
| Li et al. | Chemical remodeling cell surface glycans for immunotargeting of tumor cells | |
| Ge et al. | Folic-acid-targeted drug delivery system implementing Angelica gigas polysaccharide: A potential strategy for colorectal cancer treatment | |
| MX2025002614A (es) | Conjugados de farmaco-anticuerpo contra el factor tisular y usos de estos | |
| WO2022125891A3 (en) | Anti-cea immunoconjugates, and uses thereof | |
| MX2023001679A (es) | Inmunoconjugados de pirazolazepina y usos de estos. | |
| Kundu et al. | Polysaccharides in cancer therapy | |
| MX2023005979A (es) | Enlazadores de escisión doble de glicósido para conjugados de anticuerpo y fármaco. | |
| Kovar et al. | Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells | |
| AU2020291074A1 (en) | β-glucan composition and use therefor | |
| CN113304258B (zh) | 一种半抗原多价修饰的天然多糖偶联物及其在免疫治疗的应用 | |
| Weng et al. | Chemoenzymatic synthesis and immunological evaluation of sialyl-Thomsen-Friedenreich (sTF) antigen conjugate to CRM197 | |
| Arar et al. | A polysaccharide of Alloiococcus otitidis, a new pathogen of otitis media: chemical structure and synthesis of a neoglycoconjugate thereof | |
| Kitowski | Bio-orthogonal site-selective labelling of carbohydrates and proteins |